Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaRecruitingPhase 1 / Phase 22026-01-30NCT06926920

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Gilead Sciences180

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Asan Medical CenterSeoulSouth Korea338
John Flynn Private HospitalTugunAustralia4
Los Angeles Cancer Network (LACN) - Good SamLos AngelesUnited States1
Samsung Medical CenterSeoulSouth Korea375
Scri Oncology PartnersNashvilleUnited States156
Seoul National University HospitalSeoulSouth Korea393
Severance Hospital, Yonsei University Health SystemSeoulSouth Korea134
Siteman Cancer CenterSt LouisUnited States10
St. Vincent's Hospital - Kinghorn Cancer CenterDarlinghurstAustralia1
Sunshine Coast University Private HospitalBirtinyaAustralia10
Tennessee Oncology, PLLCNashvilleUnited States30
Texas Oncology - DFWDallasUnited States19
The University of Kansas HospitalWestwoodUnited States3
Virginia Oncology AssociatesNorfolkUnited States73
West Cancer CentreGermantownUnited States1
Winship Cancer Institute - Emory UniversityAtlantaUnited States6